Note 21: Parent Entity Information Information relating to CSL Limited (parent entity) a. Summary financial information 2025 2024 The individual financial statements for the parent entity show the following aggregate amounts: US$m US$m Profit for the year 583 448 Total comprehensive income 583 448 Current assets 111 65 Total assets 10,405 11,280 Current liabilities 137 90 Total liabilities 5,213 5,353 Contributed equity 574 557 Reserves (54) (54) Retained earnings 4,672 5,424 Net assets / Total equity 5,192 5,927 b. Guarantees entered into by the parent entity The parent entity provides certain financial guarantees in the ordinary course of business. No liability is recognised in relation to these guarantees as the fair value of the guarantees is immaterial. These guarantees are mainly related to the external debt facilities of the Group. In addition, the parent entity provides letters of comfort to indicate support for certain controlled entities to the amount necessary to enable those entities to meet their obligations as and when they fall due, subject to certain conditions (including that the entity remains a controlled entity). For information about guarantees given by the parent entity, please refer above and to Note 20. c. Commitments and contingencies The parent entity did not have any material contractual commitments for the acquisition of property, plant and equipment as at 30 June 2025 and 2024. In addition, the parent entity did not have any material contingent liabilities as at 30 June 2025 and 2024. Note 22: Non-Controlling Interests Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is the Group's only subsidiary with material non-controlling interests. VFMCRP is registered in St. Gallen, Switzerland. The Group owns 55% of the share capital and voting rights of VFMCRP, while Fresenius Medical Care (FMC) holds 45% of the share capital and voting rights. The non-controlling shareholder has certain protection rights. In the event of disagreement, the Group has the casting vote within a defined escalation process. 2025 2024 Summarised financial information (before any intercompany eliminations) of VFMCRP: US$m US$m Statement of Comprehensive Income information: Net sales 878 755 Other income 18 22 Operating profit 307 159 Net profit 302 157 Balance Sheet information: Current assets 1,371 807 Non-current assets 2,660 2,803 Current liabilities 662 297 Non-current liabilities 342 360 Equity 3,027 2,953 Statement of Cash flows information: Cash flow from operating activities 535 318 VFMCRP paid dividends of $100m during the year ended 30 June 2025 to FMC (2024: $74m). 128 Notes to the Financial Statements 128 Financial Report
RkJQdWJsaXNoZXIy MjE2NDg3